# BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer

> **NCT01669798** · PHASE2 · COMPLETED · sponsor: **AA Secord** · enrollment: 32 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** BIBF 1120

## Key facts

- **NCT ID:** NCT01669798
- **Lead sponsor:** AA Secord
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02
- **Primary completion:** 2017-09-10
- **Final completion:** 2018-02
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2018-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01669798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01669798, "BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01669798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*